Key takeawayBOCI International believes that an increase in approved products and improvements in pricing policies will jointly drive the commercialization of domestic surgical robots, although companies are at different stages of product development.
How far has the surgical robot market grown?
- In 2025, domestic surgical robot sales, including overseas sales, grew by nearly 1-fold year over year; during the same period, full-year sales in the domestic market totaled 456 units, up 17% year over year. The two figures cover different scopes.
- Surgical robots assist doctors in performing precise procedures through small incisions. Their main advantages are precise positioning and smaller incisions. BOCI International believes that advances in domestic technology, together with support from industrial policies, are ushering the sector into a period of rapid commercial development.
How are policies affecting hospital adoption?
- BOCI International notes that the medical insurance project guidelines issued in January 2026 address the key question of how surgical robots can be charged for, while also establishing a fee category for remote surgery; this could accelerate their clinical adoption across hospitals at all levels.
- Several domestic brands have received approval to market laparoscopic and orthopedic robots; downstream applications are gradually expanding from large Grade III Class A hospitals to secondary hospitals and primary-level markets.
What stages of development have the related companies reached?
- Mingzhi Electric has developed motion-control products for medical equipment, including surgical robots. These include servo motor modules, coreless motor modules and precision linear modules, which can be used in applications such as precision instrument operation. The company has made batch deliveries of related products to leading medical-device and life-sciences-instrument customers in China and overseas.
- Chunfeng Huayu, a spinal-robotics company invested in and incubated by Sanyou Medical, has completed enrollment in its registered clinical trial and entered the National Medical Products Administration’s special review procedure for innovative medical devices. The product uses a three-arm structure and supports complex procedures such as spinal deformity correction.
